how does tirzepatide different from semaglutide vs. for Weight Loss Semaglutide vs. Tirzepatide: Which GLP-1

Read the latest clinical news, personalized to your specialty

They are exploring new drug designs, improving how these drugs are delivered, and finding more uses for this class of medications

Nutrition Journal, 19 , 76

Key Takeaways Triple agonist mechanism: Retatrutide is the first medication to activate GIP, GLP-1, and glucagon receptors simultaneously GLP-1 component reduces appetite and slows gastric emptying, the core appetite suppression pathway GIP component improves insulin sensitivity and promotes favorable fat distribution Glucagon component increases energy expenditure through thermogenesis and promotes fat breakdown Weight loss: Phase 2 trials showed up to 24.2% weight loss at 48 weeks, compared to tirzepatide (~22%) and semaglutide (~15%) Investigational status: Not FDA-approved

Hydration, movement, digestive support, and consistent gut-focused habits may help improve the entire semaglutide experience long-term

Patients taking these medications saw a 12% to 14% drop in major heart events